Keryx Says It Didn't Mislead Investors On Drug's Production
Keryx Biopharmaceuticals Inc. asked a Massachusetts federal judge Wednesday to toss the sole remaining claim in an otherwise dismissed shareholders securities fraud suit, saying the stockholders' misunderstanding — not Keryx's alleged...To view the full article, register now.
Already a subscriber? Click here to view full article